This article is more than 5 years old. Information may no longer be current.

Pfizer begins trial of co-developed glaucoma treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SOPHIA ANTIPOLIS, France — Pfizer has begun the first in a series of planned clinical trials for an experimental glaucoma treatment, according to a press release from development partner NicOx.

The trial's initiation follows U.S. Food and Drug Administration clearance of the drug's investigational new drug application, which Pfizer submitted in February. The treatment, called PF-03187207, contains nitric oxide and is expected to reduce IOP.

Pfizer and NicOx co-developed PF-03187207 in August 2004. Upon initiation of the first trial, NicOx received Euro 6 million in milestone payments from Pfizer.